Ofatumumab Desensitization Protocol: A Case of Refractory Immune Thrombocytopenic Purpura

Audra L Cochran; Meredith M Schuldt; James M Quinn

doi:10.7759/cureus.46278

Ofatumumab Desensitization Protocol: A Case of Refractory Immune Thrombocytopenic Purpura

Audra L Cochran, Meredith M Schuldt, James M Quinn

Research output: Contribution to journal › Article › peer-review

Abstract

Chronic immune thrombocytopenic purpura (ITP) is an acquired hematologic condition that involves immune-mediated platelet destruction with resultant bleeding of variable severity. Refractory ITP occurs when patients fail to tolerate and/or respond to multiple treatment modalities. In this case, we examine the clinical course of a 39-year-old female with refractory ITP and discuss how we navigated a multitude of challenges by adapting an established desensitization protocol to meet our patient's needs. To our knowledge, we describe the first successful desensitization to ofatumumab for use in ITP in the current literature.

Original language	English
Pages (from-to)	e46278
Journal	Cureus
Volume	15
Issue number	9
DOIs	https://doi.org/10.7759/cureus.46278
State	Published - Sep 2023

Access to Document

10.7759/cureus.46278

Cite this

@article{247b9711738041688a73fc08ef49e15b,

title = "Ofatumumab Desensitization Protocol: A Case of Refractory Immune Thrombocytopenic Purpura",

abstract = "Chronic immune thrombocytopenic purpura (ITP) is an acquired hematologic condition that involves immune-mediated platelet destruction with resultant bleeding of variable severity. Refractory ITP occurs when patients fail to tolerate and/or respond to multiple treatment modalities. In this case, we examine the clinical course of a 39-year-old female with refractory ITP and discuss how we navigated a multitude of challenges by adapting an established desensitization protocol to meet our patient's needs. To our knowledge, we describe the first successful desensitization to ofatumumab for use in ITP in the current literature.",

author = "Cochran, {Audra L} and Schuldt, {Meredith M} and Quinn, {James M}",

note = "Copyright {\textcopyright} 2023, Cochran et al.",

year = "2023",

month = sep,

doi = "10.7759/cureus.46278",

language = "English",

volume = "15",

pages = "e46278",

journal = "Cureus",

issn = "2168-8184",

publisher = "Cureus",

number = "9",

}

TY - JOUR

T1 - Ofatumumab Desensitization Protocol

T2 - A Case of Refractory Immune Thrombocytopenic Purpura

AU - Cochran, Audra L

AU - Schuldt, Meredith M

AU - Quinn, James M

PY - 2023/9

Y1 - 2023/9

N2 - Chronic immune thrombocytopenic purpura (ITP) is an acquired hematologic condition that involves immune-mediated platelet destruction with resultant bleeding of variable severity. Refractory ITP occurs when patients fail to tolerate and/or respond to multiple treatment modalities. In this case, we examine the clinical course of a 39-year-old female with refractory ITP and discuss how we navigated a multitude of challenges by adapting an established desensitization protocol to meet our patient's needs. To our knowledge, we describe the first successful desensitization to ofatumumab for use in ITP in the current literature.

AB - Chronic immune thrombocytopenic purpura (ITP) is an acquired hematologic condition that involves immune-mediated platelet destruction with resultant bleeding of variable severity. Refractory ITP occurs when patients fail to tolerate and/or respond to multiple treatment modalities. In this case, we examine the clinical course of a 39-year-old female with refractory ITP and discuss how we navigated a multitude of challenges by adapting an established desensitization protocol to meet our patient's needs. To our knowledge, we describe the first successful desensitization to ofatumumab for use in ITP in the current literature.

U2 - 10.7759/cureus.46278

DO - 10.7759/cureus.46278

M3 - Article

C2 - 37908928

SN - 2168-8184

VL - 15

SP - e46278

JO - Cureus

JF - Cureus

IS - 9

ER -